ALK and non-small cell lung carcinoma: The EML4-ALK gene fusion incidence in Chinese NSCLC patients was approximately 3.77% (7/208), which consisted of an incidence of 15.2% (5/33)32 in female, non-smoking adenocarcinoma patients.